Gilead Jumps to Two-Year High on Covid-19 Drug Hopes

(Bloomberg) -- Gilead Sciences Inc. stock jumped as much as 7% on Thursday, reaching a two-year high, as a Piper Sandler analyst doubled down on his call on the approval prospects for the biotech c...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.